[Source: Earth Times] – TGen Drug Development (TD2) and Critical Outcome Technologies Inc. announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.
This easily synthesized small molecule compound was discovered and developed by COTI of London, Ontario, Canada. This working relationship resulted through the expanded relationship between Canadian companies and the Phoenix-based Translational Genomics Research Institute (TGen).
TD2, TGen’s Scottsdale-based drug-development subsidiary, will work with COTI to complete the Investigational New Drug (IND) enabling research necessary to gain U.S. Food and Drug Administration approval of clinical trials, perhaps by the end of 2010, and eventually move the drug to market where it can benefit patients.
For more information: TD2 and Critical Outcome Technologies Inc. Develop Novel Anti-Cancer Drug